Scaling robotic surgery in the NHS: National expenditure projections and adaptive budget-impact scenarios for soft-tissue platforms

Abstract

Background Robot-assisted soft-tissue surgery is expanding in the NHS. Policymakers need estimates of the public cash required to scale access, both in gross terms and net after accouting for existing laparoscopy costs.

Methods We built ten-year, England-wide, payer-perspective budget-impact models using 2023/24 surgical activity. Multiple platforms were simulated and grouped by capability and cost (A premium, B mid-tier, C low-cost hybrid). Nine scenarios crossed three adoption targets (30%, 50%, 90% robotic by Year 5) with three deployment mixes (Full A; Mixed A+B; Hybrid A+B for major, C for high-throughput lists). Capital was spread across Years 1-5; replacement was 4%/year in Years 6-10; consumables ramped to steady state by Year 5. The primary analysis was cash total without discounting (national expenditure projection) and a prespecified sensitivity analysis offset existing laparoscopic costs (budget impact scenario), taking into account a 20% open to robotic conversion rate. A pay-per-use (PPU) variant was explored for 90% adoption.

Results Gross programme spend rose during implementation and then stabilised as replacement dominated. At Year 5, gross spend was 0.03% (30% Hybrid), 0.14% (50% Mixed), and 0.29% (90% Full) of the NHS budget, settling by Year 10 at 0.02%, 0.09%, and 0.18%. In the budget-impact sensitivity model, displaced laparoscopy costs offset 18-45% of the robotic spend depending on scenario, yielding a lower net investment that peaks at Year 5 and settles to 0.02-0.17% of the NHS budget by Year 10. At that point, annual gross versus net spend were £0.05bn vs £0.03bn for 30% Hybrid, £0.33bn vs £0.16bn for 50% Mixed, and £0.93bn vs £0.33bn for 90% Full. PPU smoothed annual outlay at 90% adoption but did not materially change the ten-year totals. If each robotic system achieves a throughput at 350 cases per year, overall programme cost reduce by approximately 8% across scenarios.

Interpretation: Robotic expansion in the NHS appears affordable if utilisation is managed, with existing laparoscopy offsetting a meaningful share of the required spend. Flexible contracting (e.g. subscription based models) can smooth early spending without altering long-run totals. Roll-out should proceed alongside a ten-year programme of clinical outcome research to confirm cost-effectiveness and refine investment over time.